
Tylenol, Theraflu, NyQuil, and DayQuil
Allegations: Falsely marketing that phenylephrine products treat nasal congestion
Chamberlain et al. v. Johnson & Johnson Consumer Inc., RB Health LLC, GlaxoSmithKline Consumer Healthcare Holdings (US), LLC
23-cv-4435, E.D. Penn.
(Nov. 2023)
Travis et al. v. Procter & Gamble Co., Kenvue, Inc., McNeil Consumer Healthcare, Reckitt & Benckiser LLC and GlaxoSmithKline, LLC
23-cv-607, S.D. Ohio
(Sept. 2023)
Advil, Tylenol, DayQuil, NyQuil, TheraFlu, Sudafed, and other cold and flu medicines
Falsely marketing that medicines are decongestants when the active ingredient (phenylephrine) is not an effective decongestant
Pending
Allegations: Falsely marketing that phenylephrine products treat nasal congestion
Allegations: Falsely marketing that phenylephrine products treat nasal congestion
Allegations: Falsely marketing that medicines treat nasal congestion
Allegations: Falsely marketing the products treat nasal congestion
Allegations: Falsely marketing that phenylephrine products treat congestion and other cold and flu symptoms
Allegations: Falsely marketing that medicines treat nasal congestion
Allegations: Falsely marketing that medicines treat nasal congestion
Allegations: Misleadingly marketing drink mixes using the phrase “Natural fruit flavor” and images of raspberries when they contain artificial flavoring ingredients
Allegations: Misleadingly marketing products as if they treat symptoms of coughs and colds
Allegations: False natural claims
Allegations: False natural claims
A deceptive marketing trend takes root.
If you’ve been misled by an ad, regulators want to hear from you. We do too.
How negative feelings surrounding menstruation have influenced period product marketing.
Class-action lawsuits target preservative-free claims.
A closer look at what we’ll be monitoring in the new year.